JLE

European Journal of Dermatology

MENU

Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy Volume 27, numéro 6, November-December 2017

Illustrations


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

Tableaux

Auteurs
1 CHU de Poitiers, 86021 Poitiers, France
2 Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, LITEC, Université de Poitiers, 86073 Poitiers, France
3 ImageUP, STIM, ERL 7368 Université de Poitiers, 86073 Poitiers, France
* Reprints

Background

In psoriasis, a specific cytokine network has been described to play a central role in the pathophysiology of the disease. Anti-cytokine therapeutic approaches have been largely developed and TNFα constitutes the main target. Adalimumab is a human anti-TNFα monoclonal antibody that has been reported to demonstrate clinical efficacy and safety, resulting in reversal of epidermal hyperplasia and cutaneous inflammation.